This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by YIANGOU, Y. Articles by BLOOM, B. Search for Related Content PubMed PubMed Citation Articles by YIANGOU, Y. Articles by BLOOM, B.

Peptide Histidine-Methionine Immunoreactivity in Plasma and Tissue from Patients with Vasoactive Intestinal Peptide-Secreting Tumors and Watery Diarrhea Syndrome

Departments of Medicine and Histochemistry London W12 OHS, United Kingdom
Departments of Royal Postgraduate Medical School, Hammersmith Hospital London W12 OHS, United Kingdom

Address all correspondence and requests for reprints to: Prof. S. R. Bloom, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 OHS, England.

The presence of peptide histidine-methionine (PHM)-like peptides has been determined in plasma and tumor specimens from patients with vasoactive intestinal peptide (VlP)-secreting tumors and the watery diarrhea syndrome. All patients had strikingly elevated plasma concentrations of PHM immunoreactivity (median, 1800; range, 500–6800 pmol/liter; n = 12), which were higher than those of VIP (median, 235; range, 50–580 pmol/liter). In patients with other endocrine and nonen-docrine pancreatic tumors, plasma PHM concentrations were not significantly different from normal (median, 20; range, 5–60 pmol/liter; n = 28). Plasma samples from patients with diarrhea due to other illnesses also had PHM concentrations that were not significantly different from normal (median, 40; range, 10–80 pmol/liter; n = 23). The gel chromatographic profiles of plasma and tumor extracts from patients with VIP-secreting tumors revealed the presence of at least two molecular forms that reacted with an antiserum directed to the N-terminus of PHM (SY1). The later peak (K_av, 0.50–0.53) corresponded in position to synthetic PHM and also reacted with the PHM-specific antiserum (SY2). The earlier peak (K_av, 0.30–0.37), not reactive with antiserum SY2, corresponded to a large molecular form of PHM-like immunoreactivity previously identified as the predominant form in normal human stomach and plasma, though not in the rest of the intestinal tract. The neuroendocrine nature of the tumors was confirmed by the demonstration of immunostaining with a battery of antisera to neuroendocrine markers. Immunocytochemistry revealed the presence of both VIP and PHM in tumor cells. The presence of high circulating concentrations of PHM-like immunoreactivity in patients with VIP-secreting tumors, as measured with a PHM N-terminus-directed antiserum, SYl, suggests that use of this type of antiserum may provide valuable information in the diagnosis of such tumors. The contribution of the PHM-like peptides to the features of this syndrome is not known.

Received April 14, 1986.

This article has been cited by other articles:

				J. E S Ardill Circulating markers for endocrine tumours of the gastroenteropancreatic tract Ann Clin Biochem, November 1, 2008; 45(6): 539 - 559. [Abstract] [Full Text] [PDF]

				D. L.-Y. Tse, R. T.-K. Pang, A. O.-L. Wong, S.-M. Chan, H. Vaudry, and B. K.-C. Chow Identification of a Potential Receptor for Both Peptide Histidine Isoleucine and Peptide Histidine Valine Endocrinology, April 1, 2002; 143(4): 1327 - 1336. [Abstract] [Full Text] [PDF]